文献速递认知障碍与痴呆

血浆与脑脊液生物标志物诊断唐氏综合征成人阿尔茨海默病:横断面研究

Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
PubMed 文献 · Lancet Neurol · 2018-08-29

在西班牙加泰罗尼亚基于人群的健康计划中,纳入282例唐氏综合征成人(194例无症状、39例前驱期阿尔茨海默病、49例阿尔茨海默病痴呆)和67名对照,评估血浆与脑脊液生物标志物的诊断性能。血浆神经丝轻链蛋白(NfL)鉴别无症状组与前驱期组AUC为0.88,鉴别无症状组与痴呆组AUC为0.95;脑脊液多数标志物在无症状组与痴呆组比较中AUC≥0.90。作者认为血浆NfL和脑脊液生物标志物对唐氏综合征成人阿尔茨海默病有良好诊断性能。

要点

  • 血浆NfL鉴别唐氏综合征无症状组与前驱期阿尔茨海默病组AUC为0.88(95%CI 0.82-0.93)。
  • 血浆NfL鉴别无症状组与阿尔茨海默病痴呆组AUC为0.95(95%CI 0.92-0.98)。
  • 脑脊液Aβ1-42、t-tau、p-tau、NfL在无症状组与痴呆组比较中AUC均≥0.90。

核心结论

  • 血浆NfL和脑脊液生物标志物对唐氏综合征成人阿尔茨海默病具有良好诊断性能。
  • 作者认为研究结果支持血浆NfL在临床实践和临床试验中用于唐氏综合征阿尔茨海默病的早期检测。

研究设计与样本

  • 横断面研究,纳入西班牙加泰罗尼亚基于人群健康计划中18岁及以上唐氏综合征成人,有血浆或脑脊液样本者入选。
  • 参与者接受神经科和神经心理学检查及采血,部分接受腰椎穿刺;研究者在不知晓生物标志物数据的情况下将唐氏综合征成人分为无症状、前驱期阿尔茨海默病和阿尔茨海默病痴呆组。
  • 非三体对照为Sant Pau神经退行性疾病倡议中23-58岁健康年轻人的便利样本。
  • 2013年2月1日至2017年11月30日收集282例唐氏综合征参与者的血浆(194例无症状、39例前驱期、49例痴呆)和67名对照;94例参与者(分别为54、18、22例)及全部67名对照有脑脊液数据。

主要发现

  • 血浆生物标志物诊断性能较差,AUC在0.53(95%CI 0.44-0.62)至0.74(95%CI 0.66-0.82)之间,但血浆NfL除外。
  • 血浆NfL鉴别无症状组与前驱期阿尔茨海默病组AUC为0.88(95%CI 0.82-0.93),鉴别无症状组与阿尔茨海默病痴呆组AUC为0.95(95%CI 0.92-0.98)。
  • 脑脊液中除Aβ1-40(AUC 0.60,95%CI 0.45-0.75)外,无症状组与前驱期组比较各标志物AUC为:Aβ1-42 0.92(95%CI 0.85-0.99)、t-tau 0.81(95%CI 0.69-0.94)、p-tau 0.80(95%CI 0.67-0.93)、NfL 0.88(95%CI 0.79-0.96)。
  • 脑脊液生物标志物在无症状组与阿尔茨海默病痴呆组比较中性能最佳,除Aβ1-40(AUC 0.59,95%CI 0.45-0.72)外所有标志物AUC≥0.90。
  • 在唐氏综合征参与者中仅NfL浓度显示血浆与脑脊液生物标志物浓度强相关(rho=0.80;p<0.0001)。

临床怎么用

  • 作者认为研究结果支持血浆NfL在临床实践和临床试验中用于唐氏综合征成人阿尔茨海默病的早期检测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diagnosis of Alzheimer's disease in Down syndrome is challenging because of the absence of validated diagnostic biomarkers. We investigated the diagnostic performance of plasma and CSF biomarkers in this population. METHODS: We did a cross-sectional study of adults aged 18 years and older with Down syndrome enrolled in a population-based health plan in Catalonia, Spain. Every person with Down syndrome assessed in the health plan was eligible to enter the Down Alzheimer Barcelona Neuroimaging Initiative, and those with a plasma or CSF sample available were included in this study. Participants underwent neurological and neuropsychological examination and blood sampling, and a subset underwent a lumbar puncture. Adults with Down syndrome were classified into asymptomatic, prodromal Alzheimer's disease, or Alzheimer's disease dementia groups by investigators masked to biomarker data. Non-trisomic controls were a convenience sample of young (23-58 years) healthy people from the Sant Pau Initiative on Neurodegeneration. Amyloid-β (Aβ)1-40, Aβ1-42, total tau (t-tau), 181-phosphorylated tau (p-tau; only in CSF), and neurofilament light protein (NfL) concentrations were measured in plasma with a single molecule array assay and in CSF with ELISA. Plasma and CSF biomarker concentrations were compared between controls and the Down syndrome clinical groups. Diagnostic performance was assessed with receiver operating characteristic curve analyses between asymptomatic participants and those with prodromal Alzheimer's disease and between asymptomatic participants and those with Alzheimer's disease dementia. FINDINGS: Between Feb 1, 2013, and Nov 30, 2017, we collected plasma from 282 participants with Down syndrome (194 asymptomatic, 39 prodromal Alzheimer's disease, 49 Alzheimer's disease dementia) and 67 controls; CSF data were available from 94 participants (54, 18, and 22, respectively) and all 67 controls. The diagnostic performance of plasma biomarkers was poor (area under the curve [AUC] between 0·53 [95% CI 0·44-0·62] and 0·74 [0·66-0·82]) except for plasma NfL concentrations, which had an AUC of 0·88 (0·82-0·93) for the differentiation of the asymptomatic group versus the prodromal Alzheimer's disease group and 0·95 (0·92-0·98) for the asymptomatic group versus the Alzheimer's disease dementia group. In CSF, except for Aβ1-40 concentrations (AUC 0·60, 95% CI 0·45-0·75), all biomarkers had a good performance in the asymptomatic versus prodromal Alzheimer's disease comparison: AUC 0·92 (95% CI 0·85-0·99) for Aβ1-42, 0·81 (0·69-0·94) for t-tau, 0·80 (0·67-0·93) for p-tau, and 0·88 (0·79-0·96) for NfL. Performance of the CSF biomarkers was optimal in the asymptomatic versus Alzheimer's disease dementia comparison (AUC ≥0·90 for all except Aβ1-40 [0·59, 0·45-0·72]). Only NfL concentrations showed a strong correlation between plasma and CSF biomarker concentrations in participants with Down syndrome (rho=0·80; p<0·0001). INTERPRETATION: Plasma NfL and CSF biomarkers have good diagnostic performance to detect Alzheimer's disease in adults with Down syndrome. Our findings support the utility of plasma NfL for the early detection of Alzheimer's disease in Down syndrome in clinical practice and clinical trials. FUNDING: Institute of Health Carlos III, Fundació La Marató de TV3, Fundació Bancaria Obra Social La Caixa, Fundació Catalana Síndrome de Down, and Fundació Víctor Grífols i Lucas.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Fortea J, Carmona-Iragui M, Benejam B, et al. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Lancet Neurol. 2018. PMID: 30172624. doi:10.1016/S1474-4422(18)30285-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。